Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 576 of 6351
-
Can LGBTQ+-Affirmative therapy protocols reduce Self-Harm risk in youth?
Knowledge-focused CompletedAims: 1. To co-produce new intervention parts that meet the needs of LGBTQ+ people at risk of self-harm or suicidal thoughts, with LGBTQ+ people and DBT therapists. These intervention parts will be integrated into a Dialectical Behaviour Therapy (DBT) intervention, that is provi…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control Not yet recruitingThis is a single-arm, multi-center, prospective, phase II study. The primary objective is to assess the efficacy and safety of bendamustine/orelabrutinib combined with an anti-CD20 monoclonal antibody in treatment-naïve patients with mantle cell lymphoma.
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for HAE: Long-Term trial of navenibart launches
Disease control By invitation onlyThis is a Phase 3 multicenter trial in 2 parts to evaluate the long-term safety and efficacy of navenibart in adult and adolescent participants with hereditary angioedema (HAE) who participated in STAR-0215-301 (NCT06842823; ALPHA-ORBIT). Part 1 provides all participants with nav…
Phase 3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for kids with tough blood cancers: drug cocktail trial launches
Disease control Recruiting nowHEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol C is a phase I/II trial evaluating the safety and efficacy of ruxolitinib and ve…
Phase 1/2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Jun 26, 2026 17:34 UTC
-
Coffee for preemies? study tests caffeine to shield tiny kidneys
Prevention CompletedRecent observational data point towards a reduced incidence of acute kidney injury (AKI) with early caffeine use, but high-quality randomized controlled trials comparing early caffeine initiation to supportive therapy alone are lacking. This study aims to fill this critical gap b…
Sponsor: Muhammad Aamir Latif • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Rectal cancer breakthrough: could chemo replace surgery for some patients?
Disease control Recruiting nowThis study investigates the feasibility of an organ-preserving "watch-and-wait" strategy in patients with mid-to-low rectal cancer who achieve a good response after total neoadjuvant therapy (TNT). By retrospectively and prospectively analyzing patients who complete TNT following…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a targeted drug keep working after cancer progresses? new trial aims to find out
Disease control Recruiting nowThe goal of this Phase 3 clinical trial is to evaluate whether continuing cetuximab treatment beyond first-line progression can improve outcomes in patients with metastatic colorectal cancer whose tumors are RAS and BRAF wild-type. The study will compare the effectiveness of chem…
Phase 3 • Sponsor: University of Campania Luigi Vanvitelli • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Pilates may offer a new path to jaw pain relief
Symptom relief CompletedThe aim of this study is to investigate the effects of an 8-week Pilates exercise program on pain, pressure-pain threshold, temporomandibular joint (TMJ) range of motion, cervical posture, stress levels, quality of life, jaw function and disability, depression, and muscle stiffne…
Sponsor: Toros University • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Promising combo takes aim at Hard-to-Treat pancreatic cancer
Disease control OngoingThis prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer. The primary endpoint is progression-free survival (PFS), w…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New weekly shot aims to reverse fatty liver damage
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose,6mg-dose and placebo groups. The entire trial cycle includes a…
Phase 2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New inhaled antibody could help asthma sufferers breathe easier
Disease control Recruiting nowWhat is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people whose asthma is not well controlled. The study will…
Phase 2 • Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Blood test hunts hidden cancer, drug aims to stop it returning
Disease control Recruiting nowThis is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatm…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New 6-Month TB drug combo tested in diabetic patients
Disease control Not yet recruitingThe treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate. This is related to the large number of drugs in the RR-TB trea…
Sponsor: Wuhan Pulmonary Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug targets breast cancer in the brain
Disease control Not yet recruitingThis is a multi-center, open-label, two-cohort study. The purpose of this study is to evaluate the safety, tolerability and efficacy of SHR-A1811 in the treatment of HER2-positive breast cancer with brain and leptomeningeal metastases, and the efficacy and safety of SHR-A1811 in …
Phase 1/2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
New dual CAR-T attack on tough leukemia shows early promise
Disease control Not yet recruitingThis study is a single-arm, open-label, prospective clinical trial, with patients suffering from refractory and relapsed acute myeloid leukemia as the subjects. It plans to enroll 10 cases to evaluate the safety and efficacy of sequential CD123+CLL-1 CAR-T cells followed by CD7 C…
Early phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could cheap supplements cut heart failure risks? large trial launches
Disease control Recruiting nowHeart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk…
Phase 3 • Sponsor: Tor Biering-Sørensen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Nerve-Zapping procedure could boost liver cancer therapy
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line immune-targeted therapy in patients with locally advanced h…
Phase 1/2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Stomach cancer breakthrough: study seeks best Post-Surgery care for complete responders
Disease control Not yet recruitingThis study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in p…
Phase 4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 14:31 UTC
-
HIV drug combo may shield hearts: new trial launches
Disease control Recruiting nowThis randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between partic…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
MRNA therapy takes on Hard-to-Treat multiple myeloma
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC